Avantor, Inc.
AVTR-PA
New York Stock Exchange90.81
USD
+0.76
- -
CIK
0001722482
ISIN
US05352A2096
CUSIP
05352A209
Return %
Stock
S&P500
1Y
- -
16.28
3Y
- -
62.37
5Y
- -
67.63
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Stubblefield
- Full Time Employees
- 13,500
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- Radnor Corporate Center Radnor PA United States of America 19087
- IPO Date
- May 17, 2019
- CIK
- 0001722482
- Website
- avantorsciences.com
- Similar Companies
- Business
- Avantor, Inc. provides mission-critical products and services to customers in biopharma, healthcare, education, government, advanced technologies, and applied materials industries worldwide. Founded in 1904 and headquartered in Radnor, Pennsylvania, the company offers an extensive portfolio of materials and consumables including ultra-high purity chemicals and reagents under J.T.Baker brand, lab products and supplies, formulated silicone materials, customized excipients, single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips; equipment and instrumentation such as filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies; and services encompassing onsite lab and production support, equipment lifecycle management, procurement and sourcing, biopharmaceutical material scale-up and development, DNA extraction, bioreactor servicing, cleanroom control, monitoring, maintenance, and sanitization. Avantor operates across the Americas, Europe, Asia, the Middle East, and Africa through segments of Laboratory Solutions and Bioscience Production, serving over 300,000 customer locations in more than 180 countries with a catalog exceeding six million products. In 2024, Avantor entered into a definitive agreement to divest its Clinical Services business to Audax Private Equity for approximately $650 million, expected to close in the fourth quarter, enabling a sharper focus on core lab and production businesses while strengthening its balance sheet through debt reduction and after-tax cash proceeds of about $500 million. The company, which went public in 2019 on the New York Stock Exchange under ticker AVTR, continues to optimize scientific workflows via proprietary digital solutions and supports innovation from discovery to delivery with over 13,500 employees.